MinervaX ApS, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), today announces the appointment of Lidia Oostvogels as Chief Medical Officer and provides an update on its novel GBS vaccine. Lidia Oostvogels brings a wealth of experience in vaccine development with more than 25 years’ experience in clinical development. Prior to joining MinervaX, she was Senior Vice President, Area Head, Infectious Diseases and Senior Vice President, Clinical Development, for Prophylactic Vaccines CureVac AG.  

Press inquiries should be adressed to: